Donald Trump's second term has got off to a shaky start for the healthcare sector. Controversial regulatory appointments, tariffs threats and pricing disputes have all weighed on valuations. Yet the long-term outlook is compelling, driven by the challenges of an ageing global population and the opportunities for innovation created by technology.